ReviewClinics in liver disease2019
WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective.
Review in Clinics in liver disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06573190 (The Value of Fibroscan® in Assessing the Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B and Monitoring Changes by Antiviral Therapy), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Value of Fibroscan® in Assessing the Liver Status and Presence of MASLD/MASH in Patients With Chronic Hepatitis B and Monitoring Changes by Antiviral Therapy: Faraday Study
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Pooled it
- Impact of Removing the Universal Hepatitis B Birth-Dose Vaccination in the US.JAMA pediatrics · 2026Article
- Clinical burden, disease progression, and management strategies in chronic hepatitis B: implications for public health practice.Frontiers in public health · 2026Article
- Prevalence of hepatitis B virus infection and associated factors among students living on campus in South-eastern Gabon.BMC infectious diseases · 2025Article
- Real-world experience with nucleos(t)ide analogue therapy and patient survival rates in chronic viral hepatitis B treatment centers in Eritrea.Scientific reports · 2025Article
- The Hepatoprotective Effects of Ginsenoside from Ginseng: A Review of Molecular Mechanisms and Therapeutic Potentials.Current pharmaceutical biotechnology · 2025Review
- Role of viruses in periodontitis: An extensive review of herpesviruses, human immunodeficiency virus, coronavirus-19, papillomavirus and hepatitis viruses.World journal of virology · 2024Review
- Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873.ACS medicinal chemistry letters · 2024Article
- A Dual-domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Prevalence of hepatitis B and C infection and linkage to care among patients with Non-Communicable Diseases in three rural Rwandan districts: a retrospective cross-sectional study.BMC infectious diseases · 2024Article
- Prevalence of Hepatitis B Virus Infection and Associated Factors Among High School Students in Shinshicho Town, Southern Ethiopia.Health services insights · 2024Article
- Article
- Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation.Journal of clinical medicine · 2023Article
- A deep learning model with data integration of ultrasound contrast-enhanced micro-flow cines, B-mode images, and clinical parameters for diagnosing significant liver fibrosis in patients with chronic hepatitis B.European radiology · 2023Article
- Seroprevalence and Associated Risk Factors for Hepatitis B Virus among Pregnant Women Attending a Public Health Facility in Osogbo, Nigeria.Rwanda journal of medicine and health sciences · 2023Article
- An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir.Journal of clinical and translational hepatology · 2023Article
- JNK/c-Jun pathway activation is essential for HBx-induced IL-35 elevation to promote persistent HBV infection.Journal of clinical laboratory analysis · 2023Article
- Follow-up value of serum AFP and aminotransferases in chronic hepatitis B progression.Frontiers in cellular and infection microbiology · 2023Article
- Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network.Hepatology international · 2022Article
- Chronic hepatitis B: New potential therapeutic drugs target.World journal of virology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The prevalence of chronic hepatitis B (CHB) differs globally. CHB is responsible for 30% of all deaths from cirrhosis and 40% from hepatocellular carcinoma. The WHO developed guidelines in 2015 on prevention, care, and treatment of chronic HBV infection targeted to program managers in all health care settings, particularly in low- and middle-income countries. Several of the recommendations differ from those of the major Liver Societies, including the American Association for the Study of Liver Diseases (AASLD). This review highlights key differences between the AASLD and WHO guidelines and discusses the impact on management of CHB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.